China Earnings Overview: Sanofi’s OTC Slowdown, Bayer’s Glucobay Legendary Success
This article was originally published in PharmAsia News
With China the main engine of growth for multinational drug firms in emerging markets, PharmAsia News takes a closer look at companies’ China earnings, finding some strong Q3 sales figures, but slowdowns for others.
You may also be interested in...
GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
A joint venture with Minsheng Pharmaceutical Group brings Sanofi-Aventis one step closer to its goal of doubling its consumer health care business in five years and opens a powerful distribution channel in China through which the French firm can market newly acquired supplements